Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2010 Third Quarter Financial Results
Date:11/5/2010

nformation identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.Lexicon Pharmaceuticals, Inc.Selected Financial DataConsolidated Statements of Operations DataThree Months EndedSeptember 30,Nine Months Ended September 30,(In thousands, except per share data)2010200920102009(unaudited)(unaudited)Revenues:Collaborative research$  632$  1,650$  3,437$  8,042Subscription and license fees1494812181,246Total revenues7812,1313,6559,288Operating expenses:Research and development, including stock-based compensation

of $751, $733, $2,366 and $2,328, respectively20,08619,32061,41362,404General and administrative, including stock-based compensation

of $582, $547, $1,592 and $1,750, respectively4,9484,56815,53514,993Total operating expenses25,03423,88876,94877,397Loss from operations(24,253)(21,757)(73,293)(68,109)Gain on investments, net-1851411,008Interest income51103468669Interest expense(637)(785)(2,093)(2,180)Other expense, net(2,700)(516)(4,025)(2,037)Consolidated loss before taxes(27,539)(22,770)(78,802)(70,649)Income tax benefit2610226102Consolidated net loss(27,513)(22,668)(78,776)(70,547)Less: Net loss attributable to noncontrolling interest in Symphony Icon, Inc.-3,526-9,772Net loss attributable to Lexicon Pharmaceuticals, Inc.$  (27,513)$  (19,142)$  (78,776)$  (60,775)Net loss  attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted$   (0.08)$  (0.14)$  (0.27)$  (0.44)Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc.  per common share, basic and diluted337,404137,
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Lexicon to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon to Present at Morgan Stanley Global Healthcare Conference
3. Lexicon to Present at Two Major Healthcare Investor Conferences
4. Lexicon Announces Pricing of Common Stock in Public Offering
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
6. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
7. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
9. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
10. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
11. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Controlled Substance Compliance Services ... helps companies check the legal requirements around using controlled ... China. , As their international operations expand and ... software solutions built as a result of the first ...
(Date:1/22/2015)... Calif. , Jan. 22. 2015  Varian Medical Systems (NYSE: ... software, has been honored for its commitment to sustainability with ... companies. Varian is the highest ranked healthcare equipment company among ... today during the World Economic Forum at Davos, ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
(Date:12/24/2014)... December 23, 2014 Earlier this year in ... director of the Adult Stem Cell Technology Center, LLC ( ... appreciated unique property of adult tissue stem cells. His ... Past, Important for the Future,” embodied the essence of his ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... 3 Every successful originator company,will one day ... making,biosimilars development a critical part of the future ... first generation of biopharmaceuticals manufactured using,recombinant technologies was ... now nearing expiration. As with small molecule drugs, ...
... Foundation for,Biomedical Research (FBR) congratulates Congress for today ... civilian honor it can bestow, the,Congressional Gold Medal. ... improved the health of millions of American citizens ... a surgeon, inventor, educator and,medical statesman make him ...
... with Biocareercenter.com to ... 2 According to the National,Postdoc Association, more than ... United States today. With only 30 percent of,this growing ... need to find more quality jobs in the private ...
Cached Biology Technology:New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market 2New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market 3Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal 2Bio Career Center Launches First Online Jobs Board for Life Science PhDs, MDs 2
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... a comparison of the effect of different dosages of ... and maintained plasma concentrations within a range recommended by ... plasma concentrations within a lower range recommended by the ... May 1 issue of JAMA , a theme ...
... this reaction is the starting point for the synthesis ... particles, formaldehyde could be produced without the environmentally hazardous ... gold catalyst works has been found out by theoretical ... cooperation project. In the international edition of the journal ...
... led by Northwestern Medicine scientists has identified how a defective ... disease known as Giant Axonal Neuropathy, or GAN. The finding ... Investigation . GAN is an extremely rare and ... systems of young children. Those affected show no symptoms at ...
Cached Biology News:Optimal vitamin D dosage for infants uncertain 2Optimal vitamin D dosage for infants uncertain 3Mysterious catalyst explained 2Rare, lethal childhood disease tracked to protein 2
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Request Info...
Biology Products: